Pfizer’s Second Market For Targeted Lung Cancer Drug Xalkori Is Korea
This article was originally published in PharmAsia News
Executive Summary
After winning regulatory approval Dec. 29, Pfizer launches Xalkori in Korea, leveraging a clinical program that has included a significant percentage of Korean patients.
You may also be interested in...
Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
Fast As A Whip, Pfizer Files Personalized Lung Cancer Drug Crizotinib
One of three Pfizer cancer drugs to be filed in 2011, crizotinib may help to turn the tide on pipeline setbacks. Axitinib and bosutinib filings are still to come.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.